Native and Engineered Extracellular Vesicles for the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
Small Science · 2025-06 · 5 (6)
DOI: 10.1002/smsc.202400606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Science, online erschienen am 26.02.2025. Verfasst von Zhengyan Gu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences School of Pharmacy Naval Medical University Shanghai 200433 P. R. China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Innovative Research Group Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are lipid bilayer nanoparticles naturally released from cells, playing a crucial role in intercellular communication. They modulate gene expression and regulate physiological and pathological processes, including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Research has shown that EVs contain a variety of active components, are biocompatible and small in size, and do not trigger immune rejection, making the infusion of exogenous EVs a promising therapeutic tool. With further research, engineering strategies have been proposed to enhance the clinical potential of EVs. These strategies involve modifying either donor cells that secrete EVs or the EVs themselves and can be engineered to circumvent the limitations of native EVs. In this review, an overview of the biological properties of native EVs is provided and the current therapeutic potential of native and engineered EVs in treating ALI/ARDS, along with the latest research findings, is summarized. The challenges and opportunities for clinical translation of EVs as a novel therapeutic tool are also discussed, offering new insights into the treatment of ALI/ARDS using EV engineering technology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences School of Pharmacy Naval Medical University Shanghai 200433 P. R. China.
- Department of Organ Regeneration Shanghai East Hospital Tongji University School of Medicine Shanghai 200120 P. R. China.
- Lab of Toxicology and Pharmacology Faculty of Naval Medicine Naval Medical University Shanghai 200433 P. R. China.
- School of Medicine Tongji University Shanghai 200070 P. R. China.
- School of Traditional Chinese Materia Medica Shenyang Pharmaceutical University Shenyang 110006 P. R. China.
- Basic Medical Center for Pulmonary Disease Naval Medical University 800, Xiangyin Road Shanghai 200433 P. R. China.
ORCID-Profile: Kai Xiao, Ying Lu, Qingqiang Xu
Förderung
- National Natural Science Foundation of China
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Gu, Z., Xue, W., Mao, G., Pei, Z., Li, J., Sun, M., Zhang, X., Zhang, S., Li, S., Cen, J., Xiao, K., Lu, Y., & Xu, Q. (2025). Native and Engineered Extracellular Vesicles for the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome. Small Science, 5(6). https://doi.org/10.1002/smsc.202400606
Vancouver
Gu Z, Xue W, Mao G, Pei Z, Li J, Sun M, et al. Native and Engineered Extracellular Vesicles for the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome. Small Science. 2025;5(6). doi:10.1002/smsc.202400606
BibTeX
@article{Gu2025,
author = {Gu, Zhengyan and Xue, Wenjun and Mao, Guanchao and Pei, Zhipeng and Li, Jingjing and Sun, Mingxue and Zhang, Xinkang and Zhang, Shanshan and Li, Songling and Cen, Jinfeng and Xiao, Kai and Lu, Ying and Xu, Qingqiang},
title = {Native and Engineered Extracellular Vesicles for the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome},
journal = {Small Science},
year = {2025},
volume = {5},
number = {6},
doi = {10.1002/smsc.202400606}
}
EUVIMED